Genotype-Guided Treatment of Oral P2Y ₁₂ Inhibitors: Where do we Stand?

Daniel M.F. Claassens; Jurriën M. ten Berg

doi:10.2217/pgs-2019-0162

January 1, 2020PharmacogenomicsOpen Access

Genotype-Guided Treatment of Oral P2Y ₁₂ Inhibitors: Where do we Stand?

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does a personalized approach using genetic testing to de-escalate to clopidogrel benefit patient outcomes in a high risk STEMI population?

Key Points

To assess current evidence on the feasibility and clinical benefits of genotype-guided de-escalation to clopidogrel in patients presenting with ST-elevation myocardial infarction.
Assessed data from the POPular Genetics trial examining personalized antiplatelet therapy.
Used rapid genetic testing to guide P2Y12 inhibitor selection and de-escalate therapy to clopidogrel in a high-risk ST-elevation myocardial infarction (STEMI) cohort.
Personalized genotype-guided selection enabled successful de-escalation to clopidogrel and improved overall patient outcomes.
Point-of-care or rapid genetic testing proved practical and feasible for routine integration into acute clinical STEMI management.

Structured PICO

Does a personalized approach using genetic testing to de-escalate to clopidogrel benefit patient outcomes in a high risk STEMI population?

P

Population

high risk STEMI population

I

Intervention

personalized approach using genetic testing to de-escalate to clopidogrel

O

Outcome

patient outcomes

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Genotype-guided de-escalation to clopidogrel is feasible and benefits outcomes in high-risk STEMI patients.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Claassens et al. (2020) studied this question.

synapsesocial.com/papers/6a0907e3ea37c9c7dbe46b1d https://doi.org/10.2217/pgs-2019-0162

View Full Paper

Ask AI

Bookmark

Share

Genotype-Guided Treatment of Oral P2Y ₁₂ Inhibitors: Where do we Stand?

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Genotype-Guided Treatment of Oral P2Y ₁₂ Inhibitors: Where do we Stand?

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading